Join the club for FREE to access the whole archive and other member benefits.

Nature Biotechnology reviews the state of play of senolytics

12-Nov-2020

Key points from article :

In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing joint pain and stiffness.

Inhibiting MDM2 risks unleashing indiscriminate cell killing in off-target, non-senescent tissues.

Unity is now focused on the development of its BCL-xL inhibitor UBX1325 for retinal diseases.

More than two dozen other startups continue to pursue approaches to target senescent cells.

University of Florida trying to make BCL-xL blockade safer for systemic administration.

Peter de Keizer described a cell-permeable peptide comprising part of FOXO4 that could disrupt this process.

He started Cleara Biotech to make the drug more stable and targeted by introducing more unusual amino acids.

Uğur Sezerman started a company called Eternans centered around a peptide drug that directly binds to FOXO4.

To identify senescent cells, many researchers rely on imperfect proxies.

Lars Zender has developed a radioactive form of β-galactosidase that can be tracked non-invasively in the body.

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Academic

Group Lead at SENS Research Foundation.

Company Representative

Professor at Memorial Sloan-Kettering Cancer Center and founder of Atropos Therapeutics.

Academic

Professor at UCSF and co-founder of Deciduous Therapeutics.

Company Representative

Chief Executive Officer at UNITY Biotechnology.

Company

Biopharmaceutical company focused on discovering and developing drugs against aging disorders and cancer.

Academic

Research Assistant Professor at Buck Institute for Research on Aging

Company

Cleara is developing therapeutics to eliminate senescent cells.

Academic

Professor of Pharmacodynamics and Radiation Oncology at the University of Florida.

Company

Company developing a novel class of immune-modulatory therapies designed to promote a healthy lifespan.

Company

Anti-aging company developing senoblockers.

Company

Biotechnology company developing senolytic agents.

Academic

Associate Professor of Medicinal Chemistry at University of Florida.

Academic

Researcher on different aging related diseases.

Academic

Morton Goldberg Professor, Johns Hopkins University

Academic

Director and Chair in Department of Medicine at the University of Tübingen.

Company Representative

CEO, CSO and Co-Founder of SIWA Therapeutics

Academic

Professor of Molecular Genetics at the University of Exeter.

Academic

Director, Institute for Research in Biomedicine

Academic

Group Leader and Associate Professor at European Research Institute for the Biology of Ageing (ERIBA).

Company Representative

Founder and Chief Executive Officer at Oisín Biotechnologies

Academic

Immunologist and director at Center for Cell Engineering

Academic

Founding director of the Institute for Aging Research.

Company

Drug development company focused on the senolytic technology to fight age-related diseases

Company

Company that target cancer by developing senescence inducing and senolytic (senescent cell killing) compounds.

Academic

Associate Professor at Acibadem University.

Academic

Professor of Biochemistry, Molecular Biology and Biophysics at the University of Minnesota.

Academic

Professor of Molecular Carcinogenesis at the Netherlands Cancer Institute.

Academic

Cancer biologist and chair of cancer biology & genetics program at Memorial Sloan Kettering Cancer Center in US

Company

University of Exeter spinout aiming to develop senotherapeutic interventions

Company

Pharmaceutical company that develops a novel class of medicines by targeting damaged cells.

Company

Biotechnology company producing therapy that targets and destroys senescent cells.

Academia

Public land grant university in Gainesville, Florida.